Brazilian meningococcal C conjugate vaccine: Scaling up studies
Renata Chagas Bastos1, Iaralice Medeiros de Souza2, Milton Neto da Silva2
1Laboratório de Macromoléculas, Bio-Manguinhos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Abstract:
Several outbreaks caused by Neisseria meningitidis group C have been occurred in different regions of Brazil. A conjugate vaccine for Neisseria meningitidis was produced by chemical linkage between periodate-oxidized meningococcal C polysaccharide and hydrazide-activated monomeric tetanus toxoid via a modified reductive amination conjugation method. Vaccine safety and immunogenicity tested in Phase I and II trials showed satisfactory results. Before starting Phase III trials, vaccine production was scaled up to obtain industrial lots under Good Manufacture Practices (GMP). Comparative analysis between data obtained from industrial and pilot scales of the meningococcal C conjugate bulk showed similar execution times in the scaling up production process without significant losses or alterations in the quality attributes of purified compounds. In conclusion, scale up was considered satisfactory and the Brazilian meningococcal conjugate vaccine production aiming to perform Phase III trials is feasible.
Related Concept Videos
Vaccine Production
Bioequivalence studies: Biowaivers
Bioavailability Study Design: Single Versus Multiple Dose Studies
Vaccines
Viral Meningitis
Vaccinations


